论文部分内容阅读
目的研究阿托伐他汀预处理对大鼠减压病的预防作用。方法 90只健康雄性SD大鼠随机分为3组,对照组(control)、生理盐水预处理组(pr-saline)、阿托伐他汀预处理组(pr-atorvastatin),每组30只。pr-saline组和pr-atorvastatin组每日给予生理盐水预处理,pr-atorvastatin组每日给予阿托伐他汀40mg/kg预处理,在第5日预处理结束后30min,后2组进行模拟空气潜水,采用“520 Kpa-60min空气暴露,200kpa/min减压”方案,出舱后30min,观察动物的发病率和死亡率,测定肺干湿比、肺泡灌洗液白细胞含量、肺泡灌洗液中蛋白含量、肺泡灌洗液中髓过氧化物酶活力。结果 pr-atorvastatin组的大鼠减压病的发病率与死亡率较pr-saline组明显减低,其肺组织干湿比重(W/D)比值、肺泡灌洗液总蛋白和白细胞含量、肺泡灌洗液中MPO活性较pr-saline组明显降低。结论阿托伐他汀预处理,可降低减压病的发病率和死亡率,减轻减压病的炎症反应,对潜水减压病有一定的预防作用。
Objective To study the preventive effect of atorvastatin on decompression sickness in rats. Methods Ninety healthy male Sprague-Dawley rats were randomly divided into three groups: control group, pr-saline group and pr-atorvastatin group, with 30 rats in each group. The rats in pr-atorvastatin group were treated with atorvastatin 40 mg / kg daily for 30 min, and the rats in pr-atorvastatin group were given simulated air Diving, using “520 Kpa-60min air exposure, 200kpa / min decompression ” program, 30min after the capsule, the incidence of morbidity and mortality were observed, the lung wet ratio, leukocyte content of alveolar lavage fluid, Lotion protein content, alveolar lavage fluid myeloperoxidase activity. Results The incidence and mortality of decompression sickness in pr-atorvastatin group were significantly lower than those in pr-saline group. The ratio of wet / dry weight (W / D) in lung tissue, total protein and leukocyte content in BALF, MPO activity in lotion was significantly lower than pr-saline group. Conclusion Atorvastatin preconditioning can reduce the incidence of decompression sickness and mortality, relieve the inflammation of decompression sickness, and have some preventive effects on decompression sickness.